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Introduction
Screening mammography is recommended every one to 
two years in all women over age 40 and yearly for women 
over the age of  50 [1]. There are certain mammographic 
findings, including spiculated mass borders, pleomorphic 
calcifications and architectural distortion, which are suspi-
cious for malignancy and lead patients to further imaging 
work-up and subsequent biopsy. We describe a case where 
biopsy of  a suspicious mass was delayed because of  an in-
terval decrease in mass size, leading to the clinicians to as-
sume that the mass represented a benign process.
Case Report
A 63-year-old post-menopausal female presented six 
months previously for a second opinion regarding a right 
breast mass. Review of  prior outside mammograms dem-
onstrated an ill-defined nodule in the upper outer quadrant 
of  the right breast. This mass had been noted on the previ-
ous outside mammogram reports from different institutions. 
The reports that were available for review indicated that 
the mass was decreasing in size. The original mammogram 
noting the mass and any recommendations given at that 
point were not available for review. 
Six years prior to presentation, the mass measured at 9 
mm. It progressively decreased in size to 4 mm on the most 
recent mammogram (Figure 1).  Given its apparent interval 
decrease in size, the radiologist felt that this was unlikely to 
represent a malignancy and recommended a 6 month 
follow-up mammogram.  
At the 6 month follow-up, recommended by the second 
opinion at our institution, the mass remained unchanged in 
size but had slightly different shape characteristics. Addi-
tional spot compression views revealed the mass to have 
spiculated margins, a worrisome feature on mammography 
that is highly suggestive of  malignancy (Figure 2). Regard-
less of  the decrease in size of  the mass over the six years 
preceding presentation for a second opinion, biopsy was 
recommended. 
An ultrasound-guided biopsy (Figure 3) revealed invasive 
tubular carcinoma with ductal carcinoma in situ. The pa-
tient underwent lumpectomy and sentinel lymph node bi-
opsy. The excised specimen confirmed a 0.4 cm infiltrating 
tubular carcinoma, Bloom-Richardson grade 1, with a co-
existing small region of  ductal carcinoma in situ. The tubu-
lar carcinoma was estrogen and progesterone receptor 
(ER/PR) positive. The two sentinel lymph nodes were 
negative for metastatic disease. 
Of  note, the patient had a natural menopause at age 53, 
and subsequently was placed on hormone replacement 
therapy (HRT). Secondary to concerns about cardiovascu-
lar risk and increased risk for breast malignancy, the patient 
terminated her HRT use approximately five years prior to 
presentation for the second opinion. This coincides with the 
interval decrease in size of  the suspicious breast mass on 
mammography. The patient was unable to recall exact de-
tails of  her prior HRT regimen. She restarted her HRT 
(Prempro 0.3/1.5 one per day) approximately six months 
prior to presentation for a second opinion.
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Figure 1. Mammograms of the right  breast in the medial lateral oblique (MLO) projection demonstrating a mass (arrow) in the 
upper outer quadrant that is decreasing in size over six years. A, Six years prior. B, Four years prior. C, Two years prior. D, At 
presentation.
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Figure 2. Spot compression CC view of the mass (arrows) 
demonstrating spiculated margins.
3A
Figure 3. Ultrasound images of the right upper outer quadrant mass. A, Before biopsy,  the mass (between cursors) is hy-
poechoic with irregular borders and is taller-than-wide. B, During biopsy the mass is partially obscured by the biopsy needle 
(arrows).
3B
Our Investigational Review Board (IRB) does not require 
review and approval of  single case reports. 
Discussion
The effect of  HRT in causing an overall increase in 
breast tissue density is well established [2].  Depending on 
the type of  hormone replacement and how breast density is 
defined, there is a reported 17% to 73% incidence of  in-
creased breast tissue density [3]. Along the same lines, 
withdrawal of  exogenous estrogen will cause the density of  
breast tissue to decrease [4]. The Women’s Health Initiative 
demonstrated that the use of  HRT in women has been 
linked to an increase risk of  both cardiovascular events as 
well as breast cancer [5]. This data has led to many women 
to discontinue their HRT regimen [6-7].
Our case is unusual in that a biopsy proven malignancy 
decreased in size over the course of  six years, which was 
misinterpreted mammographically as representing a benign 
process. In actuality, it is likely that the estrogen-sensitive 
malignancy was decreasing in size due to withdrawal of  
exogenous hormones and progressive decrease of  endoge-
nous hormones. This situation has been described before in 
a patient who terminated her hormone therapy after the 
diagnosis of  breast cancer [8]. This is the second case re-
port that we are aware of  in which the decreasing size of  
an estrogen-sensitive solid breast mass presented a diagnos-
tic dilemma [9]. An alternative possibility, as was proposed 
in the case report by Burnside et al, is that the breast carci-
noma was spontaneously regressing. 
Imaging
Certain mammographic characteristics are suspicious for 
malignancy. These include spiculated borders of  a mass, 
pleomorphic calcifications and architectural distortion. If  
any of  these features are present on a mammogram, they 
should be reported as suspicious. The interpreting physi-
cian should not be swayed by stability or even, in this case, 
interval decrease in size of  the abnormality. This case had a 
typical, but not specific, appearance for tubular carcinoma, 
which is small, solid mass with spiculated borders.
Clinical history
When assessing the clinical presentation of  a patient in 
context with mammographic findings, the patient’s hormo-
nal status is paramount. It is not sufficient to determine if  
the patient currently uses HRT. The patient’s entire hor-
monal history, including dates of  use and replacement 
regimens, should be documented and correlated with any 
changes on mammography. 
Effect of  tamoxifen
Although this patient was not taking tamoxifen, it is pos-
sible that other patents taking this drug could show regres-
sion of  a breast carcinoma. Tamoxifen is used for the 
treatment of  breast cancer and the prevention of  breast 
cancer. This is not only true of  tamoxifen but also with 
other selective estrogen modifiers (SERM) such as ra-
loxifene. Recently reported Study of  Tamoxifen and Ra-
loxifene (STAR) trial demonstrated a 49% reduction in the 
risk of  development of  breast cancer using either hormonal 
agent [10]. This study confirmed the use of  SERM for 
chemoprevention of  breast cancer in high risk women. 
Women who are placed on SERM for chemoprevention of  
breast cancer should have a thorough radiographic evalua-
tion of  the breasts prior to the initiation of  therapy. The 
use of  SERM will need to be addressed if  a suspicious le-
sion is seen to be changing. In our experience at the Mayo 
Clinic, we have not seen regression of  lesions, but rather 
have observed progression of  lesions while on SERM lead-
ing to biopsies and the diagnosis of  cancer.
Tamoxifen has been used as neoadjuvant therapy for 
breast cancers resulting in an approximate 50% response 
rate in this setting [11]. Tamoxifen has facilitated the con-
version of  inoperable breast cancers to operable and the 
change in surgical management from mastectomy to breast 
conservation surgery in women with estrogen positive tu-
mors. Unfortunately the response rate with neoadjuvant 
hormonal therapy is not as effective as chemotherapy and is  
generally limited to elderly women with significant comor-
bidities. Utilization of  tamoxifen as primary therapy for 
breast cancer has been evaluated in two randomized trials 
comparing tamoxifen alone to surgery with adjuvant ta-
moxifen therapy [12-13]. Both these trials demonstrated a 
response rate of  approximately 50%. Unfortunately most 
women treated with tamoxifen eventually needed surgery 
for local control.
Prognosis and treatment
Infiltrating tubular carcinoma is a well-differentiated type 
of  breast cancer with a good prognosis when compared 
with invasive ductal carcinoma [14]. The natural history of 
tubular carcinoma is relatively indolent with a low inci-
dence of  systemic metastases [15-16]. Axillary spread of  
tumor occurs in approximately 13 to 20% of  patients and is  
uncommon in lesions smaller than 1 centimeter [15,17]. 
Treatment options for infiltrating tubular carcinoma are the 
same as for any other invasive breast cancer, which includes  
treatment of  the tumor with mastectomy or lumpectomy 
and staging of  the axilla using axillary lymph node dissec-
tion or sentinel lymph node biopsy [18-19]. Post-operative 
adjuvant radiotherapy after lumpectomy has also been 
shown to decrease the risk of  local recurrence not unlike 
other invasive breast cancers [20]. Our patient was treated 
using standard treatment guidelines.
Conclusion
Conventionally, an untreated breast malignancy usually 
does not decrease in size or resolve. A mass that decreases 
in size on mammography may lead to the conclusion that 
the lesion is not malignant. Our case demonstrates that this 
assumption is not always true. It is paramount that one 
evaluates the morphology of  a lesion on mammography, 
regardless of  stability or size, and correlate this with de-
tailed knowledge of  the hormonal status of  the patient. 
The most suspicious characteristic of  any lesion should 
guide the decision to perform a biopsy.
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